Cellectis S.A. (CMVLF)
| Previous close | 2.4100 |
| Open | 2.4100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.4100 - 2.4100 |
| 52-week range | 2.1900 - 9.2800 |
| Volume | |
| Avg. volume | 6 |
| Market cap | 109.814M |
| Beta (5Y monthly) | 2.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9520 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preclinical data will be presented on TALEN®-edited smart CAR T-cells overcoming key challenges of targeting solid tumors at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting. The data will be presented today in two pos
- GlobeNewswire
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published a manuscript in Frontiers Bioengineering and Biotechnology demonstrating the feasibility of efficient multiplex gene engineering using a combination of two different molecular tools: Cellectis’ TALEN® gene editing technology (TALE nuclease) an
- GlobeNewswire
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority)NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights10/31/202245,567,81051,634,701 About CellectisCellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunother
